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A B S T R A C T
Hematopoietic stem cell (HSC) transplantation is a standard approach in the treatment of hematological malignant
diseases. For the last 15 years the main source of cells for trasplantation have been peripheral blood stem cells (PBSC).
With the availability of hematopoietic growth factors and understanding the advantages of treatment with PBSC, the ap-
plication of bone marrow (BM) was supplanted. The aim of this survey was to explore the success of PBSC collection, the
factors which influence the success of PBSC collection, the composition and the quality of graft and their infuence on
hematopoietic recovery and outcome after transplantation in patients with acute myeloid leukemia (AML). PBSC were
collected by the method of leukapheresis after applying a combination of chemotherapy and growth factors or only
growth factors. The quality of graft was determined with the clonogenic progenitor cell assay and with the flow citometry
analysis. Of the total 134 patients with AML, who were submitted to HSC mobilization, the collection was successful in
78 (58.2%) patients. The collection was more successful after the first than after the second attempt of HSC mobilization
(49% vs. 11%). The criteria for effective mobilization were the number of leukocytes >3´109/L and the concentration of
CD34+ cells >20´103/mL in the peripheral blood on the first day of leukapheresis. The number of CD34+ cells infused
had the strongest impact on hematopoietic recovery. We noted significantly faster hematological recovery of neutrophils
and platelets, fewer number of transfused units of red blood cells and platelets, shorter duration of the tranfusion sup-
port, shorter treatment with intravenous antibiotic therapy and shorter hospitalization after PBSC compared to BM
transplantation. These advantages could provide their standard application in the treatment of patients with AML.
Key words: acute myeloid leukemia, autologous peripheral blood stem cells, graft composition, stem cell transplantation
Introduction
Contemporary treatment of patients with acute mye-
loid leukemia (AML) begins with the induction chemo-
therapy in order to achieve a complete remission (CR)1.
Leukemic cells are further removed with the intense con-
solidation chemotherapy. Yet there is no standard for fur-
ther treatement2. It is possible to apply chemoterapy3,
allogenic stem cell transplantation transplantation (Allo-
-SCT) or autologous stem cell transplantation (ASCT).
ASCT is adapted to wide population of patients who have
certain restrictions for treatment with Allo-SCT, such as
>45 years of age or unavailability of HLAmatched donor
hematopoietic stem cells (HSC). ASCT, unlike Allo-SCT
has a higher incidence of relapse that is explained with
the absence of positive immunological graft versus leuke-
mia reaction (GLR), insufficient in vivo purging with
consolidation chemoterapy and with the infusion of re-
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sidual leukemic cells together with the HSC graft. Lower
incidence of transplant-related mortality (TRM) is ex-
plained with the absence of graft-versus-host disease re-
action (GVHD).
ASCT can be performed using HSC from bone mar-
row (BM) or peripheral blood (PB). Given the numerous
advantages such as, faster hematopoietic recovery, lower
rates of morbidity and mortality, shorter hospitalization,
lower costs of treatment and the possibility of applying
high-dose chemotherapy to an older group of patients4–6,
peripheral blood stem cells (PBSC) has pushed the appli-
cation of HSC from BM7. Before collecting, PBSC have to
be mobilized from BM. For this purpose, the most effec-
tive is combined application of consolidation chemother-
apy and growth factors8–10 and it should be implemented
after in vivo depletion of leukemic cells, and before
hematopoietic exhaustion of BM11,12. Concentration of
circulating CD34+ cells in PB is taken as a good indicator
for making decision about when to start leukaphere-
sis13–15. The minimum yield of CD34+ cells which allows
quick hematopoietic recovery is 2´106 cells/kg. The opti-
mal yield of CD34+ cells that tends to achieve faster re-
covery is 5´106 CD34+/kg. However, the duration and the
number of leukapheresis procedures is individual and de-
pends on mobilization therapy, previous chemotherapy
and stage of disease. Processing a large volume of blood,
by large volume leukapheresis (LVL), larger number of
CD34+ cells are collected and therefore LVL is the best
choice in patients previously treated with numerous cy-
cles of chemoterapy16–18. Infusion of larger number of
CD34+ cells and colony-forming-units-granulocyte-ma-
crophage (CFU-GM) results in faster recovery of plate-
lets and neutrophils10,16–19. The quality of collecting, pro-
cessing and cryopreservating HSC product is provided by
the American Association of Blood Banks (AABB) and
the Foundation for the Accreditation of Hematopoietic
Cell Therapy (FACT) standards20,21. It includes determi-
nation of CD34+ cells quantity by flow cytometry and de-
termination of HSC viability and clonogenicity by clo-
nogenic progenitor cell assay26. The main criterion of the
HSC product quality is its repopulation ability after
transplantation.
In patients with AML, many parameters related to
mobilization, collection and quality of the graft are not
defined with certainty. Impact of the graft composition
on the kinetics of hematopoietic recovery as well as on
the outcome is unknown. In this retrospective analysis
we investigated the influence of various factors on the
success of leukapheresis procedure in patients with AML
and explored the relationship between the composition of
the graft and the hematopoietic recovery, lowering the
need for transfusion support and the frequency of com-
plications.
Patients and Methods
Patients aged 45 years, who had HLAmatched donor
of HSC, were treated with Allo-SCT. All other patients,
aged 60 years, were candidates for treatment with
ASCT and they received mobilization therapy in order to
collect stem cells. During the 1995–2005 period, 134 pa-
tients with AML were submitted to stem cell mobiliza-
tion. Diagnosis of AML was made by cytologic analysis of
PB and BM, completed with cell immunofenotyping,
cytogenetic and molecular analysis.
Treatment program
Induction therapy consisted of daunorubicine, ida-
rubicine or mitoxantrone in combination with Ara-C and
etopozide (DCE, ICE or MICE). CR was achieved if in BM
<5% blast cells were found. Afterwards, the consolida-
tion intensive chemotherapy was applied, which con-
sisted of daunorubicine, mitoxantrone or idarubicine and
intermediate-doses of Ara-C (DIA, IDIA or NOVIA). On
the day 16, for the purpose of HSC mobilization, granu-
locyte growth factor (G-CSF, Neupogen, Roche, Switzer-
land) in a dosage of 10 mg/kg/bw. s.c. daily was started un-
til the end of collection.
Collecting, processing, cryopreservation and
storage of hematopoietic progenitor cell product
HSC were collected from PB using cell separator
(COBE Spectra: Version 6.0. Gambro BCT, Lakewood,
USA). Collecting was started when the number of CD34+
cells in the peripheral blood was >10´106/L. Duration of
procedure was 4 hours23. The minimum yield was 2´106/
kg bw.24,25, and the optimum was between 3.5 and 5´106
CD34+ cells/kg bw.26. In patients who failed to collect a
sufficient number of HSC, the procedure was repeated or
BMwas taken from the posterior iliac crest, under sterile
conditions, under general anesthesia, three days after
application of G-CSF (10 mg/kg/bw. sc). The amount of
BM was about 10–15 mL/kg/bw. To final apheresis prod-
uct, autologous plasma and 10% dimethyl-sulfoxide were
added. The product was frozen under controlled condi-
tions in Planner Biomed Kryo 105 and stored in a liquid
nitrogen container at –196 °C. Clonogenic progenitor cell
assay, using MethoCult medium H4433 (StemCell Tech-
nologies, Vancouver, BC, Canada), was used to determine
the number of cells that generate CFU-GM27. The num-
ber of CD34+ cells was determined with flow cytometry
(FACScan and FACSCalibur, BD Biosciences) by using
the International Society for Hematotherapy and Graft
Engineering (ISHAGE) protocol22. Monoclonal antibod-
ies used were anti-CD45-FITC and anti-CD34-PE (BD
Biosciences, Heidelberg, Germany).
Patient monitoring
During induction and consolidation therapy and after
transplantation, clinical condition of patients was ob-
served, including signs of infections and bleeding and the
presence of other complications. Hematopoietic recovery
implied number of neutrofils >0.5´109/L and platelets
>20´109/L, without tranfusion support.
Autologous stem cell transplantation
Before transplantation patients had received myelo-
ablative chemotherapy, which consisted of high dose bu-
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sulfan 16 mg/kg/bw. orally and cyclophosphamide 120
mg/kg/bw. iv. or in minority of patients of fractionated to-
tal-body irradiation 1200 cGy total dose and cyclophos-
phamide 120 mg/kg/day iv. Immediately before infusion,
HSC product was thawed in a sterile normal saline bath
and infused to patient through a central venous catheter.
Statistical methods
This is retrospective research. The results were pro-
cessed by statistical software SPSS 17.0. Statistical sig-
nificance of differences between two arithmetic means
was tested using the t-test and between more arithmetic
means using the f-test. When analyzing correlations be-
tween variables Pearson (rp) and Spearman correlation
coefficient (rs) were used. Hematopoietic recovery after
ASCT was analyzed with the Kaplan-Meier statistical
method and the log-rank test. The value of 0.05 was
taken as the level of significance.
Results
Of the total 134 patients, 112 (83.6%) had de novo
AML, 15 (11.2%) had secondary AML and 7 (5.2%) pa-
tients had unclassified AML (Table 1). After induction
chemotherapy, which usually consisted of daunorubicune
(74.6%), idarubicine (12.7%) or mitoxantrone (6.0%) in
combination with Ara-C and etopozide (DCE, ICE or
MICE), CR was achieved in 91 (67.9%) patients. All pa-
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TABLE 1
PATIENTS CHARACTERISTICS (N=134)
Sex (m/f) 55/79
Age (median, range) 45 (4–61)
FAB subtype (%)
M0 4 (3.0)
M1 15 (11.2)
M2 56 (41.8)
M3 2 (1.5)
M4 14 (10.4)
M5 16 (11.9)
M6 4 (3.0)
M7 1 (0.7)
AML sec. 15 (11.2)
AML unclasified 7 (5.2)
No. of chemotherapy cycles to CR (%)
1 cycle 91 (67.9)
2 cycles 29 (21.6)
Unknown 14 (10.4)
Disease stage (%)
CR1 107 (79.9)
CR2 7 (5.2)
Relapse 5 (3.7)
NA 15 (11.2)
Diagnosis – ASCT interval, months
(median, range)
6 (3–14)
CR – complete remission, CR1 – first complete remission, CR2 –
second complete remission, NA – non available, ASCT – auto-
logous stem cell transplantation
TABLE 2
DETAILS OF PATIENTS TREATMENT (N=134)
Induction chemotherapy (%)
DCE 100 (74.6)
ICE 17 (12.7)
MICE 8 (6.0)
Other 9 (6.4)
Mobilization chemotherapy (%)
DIA 72 (53.7)
IDIA 17 (12.7)
NOVIA 8 (6.0)
ICE 8 (6.0)
Other 29 (21.6)
Transplantation (%)
Transplantated 115 (85.8)
Not transplantated 14 (10.5)*
NA 5 (3.7)
Transplantat type (N=115) (%)
BM 22 (19.1)
PBSC 71 (61.8)
BM + PBSC 22 (19.1)
DCE – daunorubicine + Ara-C + etopozide, ICE – idarubicine +
Ara-C + etopozide, MICE – mitoxantrone + Ara-C + etopozide,
DIA – daunorubicine + intermediate-doses of Ara-C, IDIA –
idarubicine + intermediate-doses of Ara-C, NOVIA – mitoxan-
trone + intermediate-doses of Ara-C, NA – non available, BM –
bone marrow, PBSC – peripheral blood stem cells
* 14 patients were not treated with ASCT; 5 patients did not
yield enough CD34+ cells for transplantation, 5 patients had re-
lapse of disease, 2 patients had acute hepatitis B, while in 2 pa-
tients CFU-GM colonies did not grow in culture
Fig. 1. Success of CD34+ cell collection from peripheral blood *Of
total number of patients (N=134), in 26 patients leukapheresis
was not done.
tients received consolidation therapy which consisted of
daunorubicine, idarubicine or mitoxantrone with inter-
mediate-doses of Ara-C; DIA (53.7%), IDIA (12.7%) and
NOVIA (6.0%) (Table 2). 108 (80.6%) patients were sub-
mitted to leukapheresis. In the remaining 26 (19.4%)
patients leukapheresis was not done; in 20 patients there
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TABLE 3
GRAFT CHARACTERISTICS AFTER THE FIRST AND THE SECOND MOBILIZATION OF HEMATOPOIETIC STEM CELLS (N=108)*
First mobilization therapy Second mobilization therapy
Number of leukaphereses 2 (1–5) 2 (1–5)
Total harvest (median, range)
Total nucleated cells, x108/kg 9.77 (1.30–34.45) 11.11 (81.75–44.04)
Mononuclear cells, x108/kg 4.53 (0.91–17.30) 8.24 (1.03–27.97)
CFU-GM, x104/kg 70.60 (0.00–278.34) 27.46 (0.00–135.40)
CD34+ cells, x106/kg 4.44 (0.15–42.64) 0.96 (0.03–12.50)
CFU-GM – colony-forming-units-granulocyte-macrophage
TABLE 4
THE INFLUENCE OF TOTAL NUCELATED AND MONONUCLEAR CELLS ON THE PERIPHERAL BLOOD STEM CELL COLLECTION
Patients Total nucleated cells, x108/kg Mononuclear cells, x108/kg
N X±SD (x108/kg)* p value X±SD (x108/kg)* p value
Age**** 0.257 0.152
0–10 1 14.89 10.98
11–20 3 6.01±7.30 1.92±1.47
21–30 13 8.81±6.10 5.43±4.46
31–40 13 9.10±4.46 4.62±1.50
41–50 26 12.93±7.44 5.35±2.88
51–61 22 11.05±6.84 5.11±2.51
Sex*** 0.483 0.787
Male 33 11.46±7.02 5.01±2.55
Female 45 10.37±6.49 5.19±3.27
FAB subtype**** 0.025** 0.005**
M0 3 6.43±1.97 3.13±1.76
M1 8 7.91±3.90 4.79±2.83
M2 34 11.24±5.35 5.00±2.29
M3 – – –
M4 9 5.70±3.42 2.89±1.05
M5 10 13.78±8.94 6.14±3.70
M6 3 11.90±9.34 4.95±1.26
M7 1 4.64 2.81
AML sec. 7 16.19±10.41 8.82±4.68
No. of cycles of chemotherapy to CR*** 0.452 0.931
1 cycle 59 10.69±6.43 5.15±2.84
2 cycles 15 12.15±7.68 5.22±3.53
Disease stage**** 0.092 0.119
CR1 69 11.41±6.74 5.37±2.97
CR2 3 8.61±6.61 4.47±3.75
Relapse 3 3.07±1.87 1.79±0.54
CR – complete remission, CR1 – first complete remission, CR2 – second complete remission *Data are computed on the basis of confi-
dence interval 95% **Significance on the value of 0.05 ***t-test ****f-test
was no increase of CD34+ cells in the peripheral blood af-
ter chemotherapy, 1 patient had acute hepatitis B, 1 pa-
tient had relapse of disease, and for 4 patients there were
no data. Of the total number of patients, PBSC collection
was successful in 78 (58.2%) patients. As a criterion of
succesful collection a total yield of 2´106/kg CD34+ cells
was taken. Collecting was much more successful after
the first attempt to mobilize HSC (Figure 1). Graft char-
acteristics after the first and the second attempt of HSC
mobilization are shown in Table 3.
115 (85.8%) patients were treated with ASCT, 71 pa-
tients (61.8%) with PBSC, 22 patients (19.1%) with BM,
and 22 patients (19.1%) with PBSC and BM (Table 2). In
109 (94.8%) patients myeloablative chemotherapy con-
sisted of busulfan and cyclophosphamide, 1 (0.9%) pa-
tient received cyclophosphamide with total-body irradia-
tion, 2 (1.7%) patients received busulfan, cyclophospha-
mide and etopozide, 1 (0.9%) patient received busulfan,
cyclophosphamide and idarubicine, and for 2 (1.7%) pa-
tients there were no data. Examinating the influence of
the factors on the HSC collection, as shown in Tables 4
and 5, sex, number of chemotherapy cycles to achieve
complete remission and stage of disease did not have a
significant impact on the collection of total nucleated
cells, mononuclear cells, CFU-GM and CD34+ cells. Pa-
tient age had a significant impact on the collection of
CFU-GM, but did not affect the collection of total nucle-
ated cells, mononuclear cells and CD34+ cells. Patients
aged 21–30 and 31–40 years of age collected an average of
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TABLE 5
THE INFLUENCE OF COLONY-FORMING-UNITS-GRANULOCYTE-MACROPHAGE AND CD34+ CELLS ON THE PERIPHERAL BLOOD
STEM CELL COLLECTION
Patients CFU-GM, ´104/kg CD34+ cells, ´106/kg
N X±SD (´108/kg)* p value X±SD (´108/kg)* p value
Age**** 0.027** 0.453
0–10 1 125.40 2.71
11–20 3 1.76±2.49 10.11±11.85
21–30 13 59.18±53.70 6.93±11.17
31–40 13 50.17±27.80 8.84±10.99
41–50 26 95.56±52.19 4.52±2.62
aauto51–61 22 95.93±72.69 5.42±3.45
Sex*** 0.592 0.114
Male 33 84.17±67.30 7.78±9.97
Female 45 76.68±53.14 4.85±3,53
FAB subtype**** 0.074 0.730
M0 3 59.77±11.22 5.36±1.11
M1 8 55.49±46.87 5.64±5.37
M2 34 76.43±57.58 6.02±7.74
M3 – – –
M4 9 41.54±22.92 3.23±3.04
M5 10 111.97±54.55 9.72±11.83
M6 3 72.90±13.81 4.66±2.10
M7 1 24.32 7.2
AML sec. 7 121.65±91.34 4.39±2.49
No. of cycles of chemotherapy to CR*** 0.388 0.607
1 cycle 59 81.38±60.81 6.50±7.62
2 cycles 15 66.58±37.43 5.42±5.59
Disease stage**** 0.196 0.710
CR1 69 83.99±59.65 6.11±7.17
CR2 3 96.60 9.23±12.26
Relapse 3 21.10±25.37 4.54±3.49
CR – complete remission, CR1 – first complete remission, CR2 – second complete remission, CFU-GM – colony-forming-units-gra-
nulocyte-macrophage *Data are computed on the basis of confidence interval 95% **Significance on the value of 0.05 ***t-test
****f-test
less, and patients aged 41–50 and 51–60 years of age col-
lected an average of more CFU-GM. Subtype of AML sig-
nificantly affected the collection of total nucleated cells
and mononuclear cells and did not impact the collection
of CFU-GM and CD34+ cells. The most total nucleated
and mononuclear cells were collected in patients with
AML-M5 and AML-M6 and in patients with AML-M2, as
well as in patients with secondary AML.
Number of days to WBC >1´109, number of days
from the start of consolidation chemotherapy to the first
leukapheresis, leukocyte count in peripheral blood>3´109/L
and the concentration of CD34+ cells >20´103/mL on the
first day of leukapheresis have shown significant impact
on the collection of CD34+ cells (Table 6).
The influence of graft composition on the hematologi-
cal recovery is shown in Tables 7 and 8. Of all parameters
tested, number of total nucleated cells infused had a posi-
tive influence only on neutrophil hematopoietic recovery,
while the number of mononuclear cells infused did not
have significant impact on hematopoietic recovery. The
number of CD34+ cells infused had the strongest impact
on hematopoietic recovery and the number of the CFU-
-GM infused had a positive impact on most parameters of
hematopoietic recovery. The number of CD34+ cells in
the graft had a positive influence on neutrophil and
platelet recovery, on the number of transfused units of
red blood cells and platelets, on the duration of the trans-
fusion support and on the number of days of intravenous
antibiotic therapy as well as on the length of hospitaliza-
tion.
After ASCT with PBSC, when compared to BM in
those patients who were not able to collect PBSC, hema-
topoietic recovery of neutrophils and platelets was signif-
icantly faster, number of transfused blood units was
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TABLE 6
INFLUENCE OF FACTORS ON THE COLLECTION OF CD34+ CELLS AFTER THE FIRST MOBILIZATON THERAPY
Patients Correlation p value
N rP
Days to WBC >1 x 109/L post consolidation chemotherapy 72 –0.247 0.037*
Days to harvest post consolidation therapy 69 –0.311 0.009*
WBC on the first day of harvest
<3 x 109/L 14 0.543 0.178
>3 x 109/L 62 0.350 0.005*
Concentration of CD34+ cells in peripheral blood on the first day of harvest
<20 x 103/Ml 32 0.096 0.601
>20 x 103/Ml 34 0.854 0.000*
rP – Pearson correlation coefficient; * Significance on the value of 0.05
TABLE 7
THE INFLUENCE OF TOTAL NUCLEATED CELLS AND MONONUCLEAR CELLS ON THE HEMATOPOIETIC RECOVERY AFTER
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
Patients
N
Total nucleated cells Mononuclear cells
Correlation
coefficient rS
p value
Correlation
coefficient rS
p-value
Days to neutrophil count >0.5 ´ 109/L 83 –0.347 0.001* –0.131 0.237
Days to platelet count >20 ´ 109/L 52 –0.017 0.906 –0.087 0.538
No. of red blood cells units 87 –0.092 0.396 –0.066 0.542
No. of platelet units 88 –0.119 0.269 0.043 0.689
Last day of transfusion support post transplantation
Red blood cell transfusion 81 –0.099 0.379 –0.001 0.989
Platelet transfusion 86 –0.033 0.761 0.059 0.589
No. of febrile days 87 –0.083 0.444 –0.061 0.572
No. of febrile episodes 86 –0.137 0.208 –0.082 0.453
No. of days on intravenous antibiotic treatement 85 –0.132 0.229 –0.100 0.361
Days of hospitalization 92 –0.151 0.152 0.008 0.940
rS – Spearman correlation coefficient; * Significance on the value of 0.05
lower, duration of transfusion support, intravenous anti-
biotic treatment and the lenght of hospitalization were
shorter, while number of febrile days and febrile episodes
did not differentiate after ASCT with PBCT or BM (Ta-
ble 9).
Discussion and Conclusion
Although the use of PBSC for transplantation signifi-
cantly increased through last 15 years, many questions
in this field are still unanswered. The application of HSC
in particular is little explored in patients with AML be-
cause there were doubts about their poor hematopoietic
potential.
In our study CR was achieved after one cycle of induc-
tion chemotherapy in 91 (67.9%) patients with AML,
which corresponds to the results of other surveys in AML
patients28–30. In the study by Zittoun et al. CR was
achieved in 576 patients (61.2%)28. J. Harousseau and as-
sociates included 504 patients and after induction che-
motherapy achieved CR in 338 (67.1%) patients29, and in
the research by Cassileth et al. CR was achieved in 414
(56%) patients30.
Mobilization therapy using growth factor after con-
solidation chemotherapy was effective in most our AML
patients (58.2%) but this proportion is substantially low-
er in comparison to patients with lymphoproliferative
diseases; non-Hodgkin lymphoma (NHL) and multiple
myeloma (MM). The median number of leukapheresis
procedures was 2 (range, 1–5). Failure to collect a mini-
mum number of HSC (2´106/kg) for transplantation
was previously reported in a significant number of pa-
tients (up to 40%), depending on type of disease and in-
tensity of applied chemotherapy and radiotherapy23. In
the work of D’Arene et al.31 patients with various malig-
nant diseases were included and collection was successful
(2.5´106/kg) in 75% of patients. In the group of patients
who did not successfully collect HSC, large proportion
(41%) consisted of patients with AML. Lee et al.32 also in-
cluded patients with various malignant hematological
diseases and successfully collected HSC in 71% of pa-
tients. However, they did not report results according to
the type of disease. Visani et al.33 successfully collected
stem cells (2´106/kg) in 23 (79%) patients with AML,
and Lee and associates19 included 34 patients with AML
and successfully collected stem cells in 33 patients. In the
last two studies, sample was small and did not include
patients with secondary AML as well as patients with
previously diagnosed myelodisplasia which could con-
tribute to the lower collection. Median number of CD34+
cells after the first attempt to mobilize HSC in our sur-
vey (4.44´106/kg) is comparable to number of CD34+
cells obtained in other studies.
In the study of Lee et al.19 median number of CD34+
cells in patients with AML was 4.84´106/kg (range 0.18–
19.6). Median number of CD34+ cells in HSC products in
patients with various malignant hematological diseases
was higher, 5.43´106/kg (range 0.03–60.16)32. In our sec-
ond attempt of mobilization, success of HSC collection
was poorer in comparison to the first attempt of mobili-
zation (8.2% vs. 49.3%). In AML patients HSC collection
is still insufficiently explored and is less efficient than in
patients with other malignant diseases.
Success of mobilization is quite variable among pa-
tients, depending on certain factors such as age, the
amount of previous chemotherapy and radiotherapy, type
of malignant disease and degree of BM involvement with
disease. Those were the factors that can affect the collec-
tion of HSC in patients with various malignant hemato-
logical diseases13. In general, AML is considered as a bad
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TABLE 8
THE INFLUENCE OF COLONY-FORMING-UNITS- GRANULOCYTE-MACROPHAGE AND CD34+ CELLS ON THE HEMATOPOIETIC
RECOVERY AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
Patients
N
CFU-GM CD34+ cells
Correlation
coefficient rS
p value
Correlation
coefficient rS
p value
Days to neutrophil count >0.5´109/L 80 –0.598 0.000* –0.418 0.000*
Days to platelet count >20´109/L 52 –0.196 0.163 –0.275 0.049*
No. of red blood cells units 83 –0.278 0.011* –0.402 0.000*
No. of platelet units 84 –0.422 0.000* –0.514 0.000*
Last day of transfusion support post transplantation
Red blood cell transfusion 78 –0.251 0.027* –0.499 0.000*
Platelet transfusion 82 –0.354 0.001* –0.598 0.000*
No. of febrile days 83 –0.082 0.464 –0.179 0.097
No. of febrile episodes 82 –0.162 0.147 –0.197 0.069
No. of days on intravenous antibiotic treatement 81 –0.199 0.075 –0.379 0.000*
Days of hospitalization 88 –0.445 0.000* –0.588 0.000*
rS – Spearman correlation coefficient, CFU-GM – colony-forming-units-granulocyte-macrophage; * Significance on the value of 0.05
prognostic factor for HSC collection, due to often resis-
tant nature of disease, intensive cytotoxic chemotherapy
and prolonged cytopenia caused by the exhaustion of
hematopoietic reserves19,34. In this research, the collec-
tion of total nucleated cells, mononuclear cells, CFU-GM
and CD34+ cells was not different in patients who re-
ceived one or two cycles of induction chemotherapy. Also,
in other studies in AML patients, the number of cycles of
induction chemotherapy to achieve complete remission
or number of cycles of induction chemotherapy to HSC
mobilization did not affect the collection of stem cells19,34.
These results are different from the results in other ma-
lignant hematological diseases. Study of patients with
lymphoma showed that each cycle of chemotherapy re-
duces the number of CD34+ cells by 0.2´106/kg and irra-
diation by 1.8´106/kg per leukapheresis35. In the studies
of patients with MM, >6 cycles of chemoterapy36 and BM
involvement with disease37 significantly reduces the
number of CD34+ cells. Explanation why number of in-
duction chemotherapy cycles does not affect the collec-
tion of HSC in patients with AML can be found in earlier
observations that standard type of chemotherapy with
Ara-C and antracycline, used in treatment of AML pa-
tients, has less harmful effect on normal stem cells, than,
for example, alkylating agens do38. In addition, mobiliza-
tion therapy for AML patients usually consists of 1 or 2
cycles of chemotherapy in contrast to the treatment of
lymphoma patients where radiotherapy is frequently ap-
M. Raos et al.: Graft Composition in Acute Myeloid Leukemia, Coll. Antropol. 34 (2010) 1: 105–115
112
TABLE 9
COMPARISON OF THE HEMATOPOIETIC RECOVERY AFTER AUTOLOGOUS TRANSPLANTATION OF BONE MARROW AND
PERIPHERAL BLOOD STEM CELLS
Patients (N) X±SE* p value
Days to neutrophil count >0.5 x 109/L*** 0.000**
BM 17 28.53±1.84
PBSC 61 13,97±0.40
Days to platelet count >20 ´ 109/L*** 0.001**
BM 3 44±3.06
PBSC 46 12.80±0.59
No. of red blood cells units*** 0.000**
BM 18 7.56±0.87
PBSC 62 2.68±0.28
No. of platelet units*** 0.000**
BM 18 115.83±18.42
PBSC 62 22.07±2.81
Last day of transfusion support post transplantation***
Red blood cell transfusion 0.000**
BM 17 36.71±3.34
PBSC 55 10.62±1.28
Platelet transfusion 0.000**
BM 17 45±3.63
PBSC 60 13.90±1.22
No. of febrile days*** 0.616
BM 19 4.37±1.15
PBSC 61 3.80±0.42
No. of febrile episodes*** 0.543
BM 19 1.16±0.12
PBSC 60 1.07±0.07
No. of days on intravenous antibiotic treatement*** 0.000**
BM 17 21.77±3.03
PBSC 59 13.17±0.72
Days of hospitalization*** 0.000**
BM 19 46.90±3.90
PBSC 66 21.32±0.86
BM – bone marrow, PBSC – peripheral blood stem cells, *Data are computed on the basis of confidence interval 95% **Significance on
the value of 0.05 ***Kaplan-Meier test
plied together with several cycles of chemotherapy (usu-
ally 6 cycles)35. By testing the influence of age, gender,
subtype and stage of disease, we did not find a significant
difference in the collection of CD34+ cells. However, we
demonstrated a significant impact of the subtype of dis-
ease on the collection of total nucleated and mononuclear
cells and of the patient age on the collection of CFU-GM.
It is the question of hematopoietic reserve in these group
of patients and the mechanism by which above men-
tioned parameters affected the graft composition. Many
studies did not find positive impact of patient age and
gender on the HSC collection19,34,35. However, the suc-
cessful collection of HSC is shown in patients with a
shorter period (<2 months) from diagnosis to leukaphe-
resis19. We observed successful collection of CD34+ cells
in patients with shorter period to harvest after the con-
solidation chemotherapy. Furthermore, we have shown
successful collection of CD34+ cells in patients with
faster recovery to WBC >1´109/L post consolidation che-
motherapy. Other authors have shown the same. In the
group of AML patients Jowit et al. found that shorter pe-
riod to harvest HSC post consolidation chemotherapy
and faster leukocyte recovery results in larger number of
HSC collected34. Interpretation arises from an assump-
tions about a better reserve and hematopoietic potential
of HSC in these patients. Collection of CD34+ cells was
also more successful in patients with faster platelet re-
covery post induction therapy and in patients with hi-
gher platelet number on the first day of leukapheresis
(>20´109/L), which indicates that the speed of platelet
recovery is a good indicator of hematopoietic BM re-
serves. However, it is not proven that the speed of neu-
trophil recovery post induction therapy influences the
collection of CD34+ cells34. In patients with MM faster
platelet recovery post chemotherapy (>50´109/L) resulted
in collection of a significantly larger number of CD34+
cells36.
Collection of a good quality graft depends on the effec-
tive mobilization of HSC and on the moment when
leukapheresis starts18. We found a significant correlation
between the number of leukocytes on the first day of
leukapheresis and the success of HSC collection when
the number of leukocytes was >3´109/L. We also shoved
the same positive correlation with the concentration of
CD34+ cells in peripheral blood of >20´103/mL. This is
in agreement with the results of other authors who have
also observed that patients who have concentration of
CD34+ cells >20´103/mL in peripheral blood, on the first
day of leukapheresis, have a greater yield of CD34+ cells
in leukapheresis product in comparison to patients with
a lower concentration of CD34+ cells in peripheral
blood18. Above mentioned factors however, only partially
explained variability in kinetics to mobilize HSC. In
healthy donors, who have normal BM function and did
not receive chemotherapy, the use of G-CSF (5–16 mg/kg)
also resulted in variations in collecting CD34+ cells. Ap-
proximately 5–15% of healthy donors fails to collect a
sufficient number of CD34+ cells10.
ASCT has to ensure complete hematopoietic and im-
mune recovery after the application of high doses of
chemotherapy18. The number of total nucleated cells,
mononuclear cells, CFU-GM or CD34+ cells has been ap-
plied as a measure of hematopoietic potential of HSC in
the graft34. It is considered that the minimum number of
2´106/kg CD34+ cells4,19–33, and the optimal number of
5´106/kg ensures rapid hematological recovery within
two weeks18,39. Threshold of 5´106 CD34+ cells/kg is not
absolute, and approximately half of patients who are
transplanted with 2.5–5´106/kg cells, still have a quick
hematological recovery. Patients who are transplanted
with larger number of HSC, have faster platelet reco-
very39. With a number of CD34+ cells lower than the
minimum stated above, hematopoietic recovery is possi-
bly prolonged and incomplete. After infusion <2´106/kg
CD34+ cells, because of the slow hematopoietic recovery,
very little or any benefits are expected from PBSC trans-
plantation in comparison to BM. Also, HSC threshold
sholud be higher for the transplantation of patients who
were previously long-treated with chemotherapy. Thres-
hold of CD34+ cells that ensures rapid hematologic re-
covery, in patients who were treated with melphalan <6
months, is 2.5´106 CD34+ cells/kg, while in patients who
were treated with melphalan >12 months, is >5´106/kg
CD34+ cells36.
In this study we showed a significant correlation be-
tween the number of CFU-GM and CD34+ cells infused
and the speed of neutrophil recovery. We also showed a
significant correlation between the number of CD34+
cells infused and the speed of platelet recovery. Other pa-
rameters of hematologic recovery did not significantly
depend on the number of CFU-GM infused. Other stud-
ies of patients with AML have shown a significant rela-
tionship between the number of CFU-GM infused and
the recovery of neutrophils and platelets or between the
number of CD34+ cells infused and the recovery of neu-
trophils and platelets. After transplantation of 4.40´
104/kg CFU-GM, the neutrophil recovery (>0.5´109/L)
was reached in 12 days and the platelet recovery
(>20´109/L) in 29 days34. After the transplantation of
3.51´106/kg CD34+ cells, the neutrophil recovery was
reached in 11 days and the platelet recovery in 20 days.
Numbers of total nucleated cells and mononuclear cells
infused do not show a significant correlation with the he-
matological recovery (p=0.062 and p=0.701)19. When
evaluating total nucleated cells and mononuclear cells
we demonstrated a significant correlation between the
number of total nucleated cells infused and the speed of
neutrophil recovery. Number of CD34+ cells infused had
a significant correlation with all studied parameters of
hematological recovery except with the number of febrile
days and febrile episodes. Today, CD34+ cells and CFU-
-GM are applied as a replacement markers for hemato-
poietic stem cells19,34.
In this study we compared hematopoietic recovery af-
ter PBSC and BM transplantation. Of note is, that our
patients transplantated with BM were those who were
unable to collect PBSC for transplantation. Due to small
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number of data we were unable to interprete the speed of
platelet recovery after PBSC and BM transplatation. In
some studies median days to neutrophil recovery after
PBSC transplantation or BM transplantation was 16 to
37 days and to platelet recovery 14 to 96 days, respec-
tively4. In the Italian study median days to neutrophil re-
covery after PBSC transplantation or BM transplanta-
tion was 17 to 36 days and to platelet recovery 20 to 150
days, respectively33. Sirohi and associates made the same
comparison and showed neutrophil recovery >0.5´109/L
in 14 and 33 days, and platelet recovery >20´109/L in 18
and 36 days36. According to this, duration of transfusion
support and length of hospitalization were shorter after
PBSC transplantation. In the study by Visani and asso-
ciates33 duration of red blood cell transfusion support, af-
ter PBSC transplantation was 22 days in comparison to
130 days after BM transplantation and duration of plate-
let transfusion support was 34 and 119 days, respeciti-
vely. Accordingly, the lenght of hospitalization was 19
and 34 days, respectively. This study indicates the advan-
tage of PBSC graft in relation to BM graft because of sig-
nificantly shorter time needed for hematological recov-
ery, lesser transfusion support with red blood cells and
platelets, shorter treatment with intravenous antibiotic
therapy and shorter hospitalization time. Faster hema-
topoietic recovery after PBSC transplantation can be ex-
plained with the transplantation of larger number of
stem cells or stem cells with greater hematological po-
tential4. There are other advantages of collecting PBSC:
avoiding general anesthesia and the need for operating
room and complications associated with BM harvesting
(pain, bleeding and infections)4. Accordingly, TRM is re-
duced (1% vs. 5–14%)40,41. Therefore, application of
PBSC is in patients with malignant hematological dis-
eases justifingly increasing. Since PBSC provides faster
hematopoietic recovery, treatment can be extended to a
group of patients of older age19. In addition, PBSC trans-
plantation significantly reduces the length of hospitaliza-
tion and overall costs of treatement39. In AML patients,
many researchers have expressed doubts about ASCT,
though it is, for example, standard treatment for MM41.
Slow hematopoietic recovery in patients with AML after
BM transplantation was related to the impossibility to
collect the sufficient number of HSC for transplantation
or to their lower potency for hematopoietic recovery4.
Also, there were doubts about adequacy of treating pa-
tients with AML in first remission as well as with good
cytogenetic risk factors and lower risk of relapse15. In
conclusion it can be said that the number of leukocytes
>3´109/L and the concentration of CD34+ cells in the pe-
ripheral blood >20´103/mL on the first day of leuka-
pheresis are good indicators of effective HSC mobiliza-
tion. Furthermore, as infused number of CD34+ cells
have the strongest influence on all parameters of hema-
tological recovery, their number in graft is the best indi-
cator of hematological recovery after PBSC transplanta-
tion. Likewise, hematopoietic recovery was significantly
faster and the number of complications significantly
lower after PBSC transplantation in relation to BM
transplantation, which justifies a standard application of
this method in the treatment of patients with AML.
However, a lower mobilization potential in AML patients
still remains a problem that needs to be resolved. Also,
some studies have shown a positive impact of a larger
yield of CD34+ cells on the incidence of relapse, whether
the patients were transplantated or not. This observa-
tion needs further exploration and verification. More-
over, transplant type (PBSC or BM) regarding to the inci-
dence of relapse is insufficiently explored and needs
more research.
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SKUPLJANJE I SASTAV TRANSPLANTATA AUTOLOGNIH KRVOTVORNIH MATI^NIH
STANICA PERIFERNE KRVI U BOLESNIKA S AKUTNOM MIJELOI^NOM LEUKEMIJOM:
UTJECAJ NA HEMATOLO[KI OPORAVAK I ISHOD
S A @ E T A K
Transplantacija krvotvornih mati~nih stanica (KMS) standardan je pristup lije~enja hematolo{kih zlo}udnih bolesti.
Unazad 15 godina glavni izvor stanica za transplantaciju ~ine KMS periferne krvi. Dostupno{}u hematopoetskih ~im-
benika rasta i spoznajom predosti lije~enja KMS periferne krvi potisnuta je primjena ko{tane sr`i (KS). Svrha ovog rada
bila je istra`iti u~inkovitost skupljanja KMS iz periferne krvi, ~imbenike koji utje~u na uspje{nost skupljanja KMS iz
periferne krvi, sastav i kvalitetu transplantata te njihov utjecaj na hematolo{ki oporavak i ishod nakon lije~enja trans-
plantacijom u bolesnika s akutnommijeloi~nom leukemijom (AML). U ovom istra`ivanju KMS periferne krvi skupljane
su postupkom leukafereze nakon kombinacije kemoterapije i faktora rasta ili samo faktora rasta. Kvaliteta pripravka
KMS odre|ena je metodom kratkotrajne kulture stanica »in vitro« i metodom proto~nocitometrijske analize. Od 134
bolesnika s AML, kod kojih je u~injen poku{aj mobilizacije KMS, skupljanje je bilo uspje{no kod 78 (58,2%) bolesnika.
Skupljanje je bilo uspje{nije nakon prvog nego nakon drugog poku{aja mobilizacije KMS (49% vs. 11%). Kriteriji u~in-
kovite mobilizacije bili su broj leukocita >3x109/L i koncentracija CD34+ stanica >20x103/mL u perifernoj krvi na prvi
dan leukafereze. Broj infundiranih CD34+ stanica imao je najja~i utjecaj na hematolo{ki oporavak. Tako|er smo uo~ili
zna~ajno br`i hematolo{ki oporavak neutrofila i trombocita, manji broj transfundiranih doza koncentrata eritrocita i
trombocita, br`e postizanje neovisnosti o transfuzijama koncentrata eritrocita i trombocita, kra}i broj dana intraven-
skog lije~enja antibioticima i kra}i boravak u bolnici nakon transplantacije KMS periferne krvi u odnosu na trans-
plantaciju KS. Ove prednosti mogle bi osigurati njihovu standardnu primjenu u lije~enju bolesnika s AML.
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